Common Myths About Spravato Treatment: What Patients at Healing and Psychiatry in Flagstaff Should Actually Know

When exploring treatment options for treatment-resistant depression, patients often encounter a wave of conflicting information online. Questions like “is IV ketamine better than Spravato?” dominate search results, and well-meaning advice from friends or forums can sometimes blur the line between fact and fiction. At Healing and Psychiatry in Flagstaff, AZ, we believe that informed patients make better decisions about their mental health care. That is why we are addressing some of the most persistent myths about Spravato (esketamine) nasal spray – so you can approach your treatment journey with clarity and confidence.

What Is Spravato, and Why Does It Matter in 2026?

Before we address the myths, it helps to understand what Spravato actually is. Spravato is an FDA-approved nasal spray containing esketamine, which is a derivative of ketamine. It was specifically approved for adults with treatment-resistant depression (TRD) and, more recently, for major depressive disorder with suicidal ideation in adults. Unlike traditional antidepressants that may take weeks to produce noticeable effects, Spravato has been shown to offer more rapid improvement in depressive symptoms for many patients.

Spravato is administered in a certified healthcare setting under direct medical supervision. Patients remain at the clinic for a monitoring period after each session to ensure safety and comfort. At Healing and Psychiatry, serving patients throughout Flagstaff and the broader Northern Arizona region, Spravato treatment is delivered in a professional, supportive environment designed to prioritize patient well-being at every step.

Myth #1: IV Ketamine Is Always Superior to Spravato

One of the most common questions patients bring to their initial consultations is whether IV ketamine is better than Spravato. The short answer is that neither treatment is universally “better” – each has distinct characteristics that may make it more appropriate for different patients and clinical situations.

Understanding the Differences

IV ketamine and Spravato share a pharmacological foundation, but they differ in meaningful ways. IV ketamine uses racemic ketamine (a mixture of two molecular forms) delivered intravenously, while Spravato uses only the S-enantiomer (esketamine) delivered as a nasal spray. Here are some of the practical distinctions:

• FDA approval status: Spravato is FDA-approved specifically for treatment-resistant depression and major depressive disorder with suicidal thoughts. IV ketamine is used off-label for depression, meaning it has not received FDA approval for that specific indication.
• Administration method: Spravato is a self-administered nasal spray (under clinical supervision), while IV ketamine requires intravenous access and infusion equipment.
• Regulatory oversight: Because of its FDA-approved status, Spravato is subject to a Risk Evaluation and Mitigation Strategy (REMS) program, which includes specific safety protocols and monitoring requirements.
• Treatment protocols: Spravato follows a standardized dosing schedule established through clinical trials, providing a structured and evidence-based treatment framework.

When patients ask whether IV ketamine is better than Spravato, the most responsible answer is that the right choice depends on individual clinical circumstances. Factors such as diagnosis, treatment history, medical conditions, and patient preference all play a role. The team at Healing and Psychiatry works with each patient individually to determine the most appropriate course of care.

Myth #2: Spravato Is Just a Recreational Drug in a Medical Wrapper

This myth stems from the broader association between ketamine and its history as a substance of misuse. While it is true that ketamine has been used recreationally, this characterization fundamentally misrepresents the clinical application of Spravato.

The Clinical Reality

Spravato underwent rigorous clinical trials before receiving FDA approval in 2019. These studies evaluated its safety, efficacy, and appropriate dosing in controlled medical environments. The medication is classified as a Schedule III controlled substance, and its distribution is tightly regulated through the REMS program. This means:

• Spravato can only be administered in a certified healthcare facility.
• Patients must be monitored by a healthcare provider for a minimum period after each dose.
• The medication cannot be taken home or self-administered outside the clinic.
• Patients cannot drive or operate heavy machinery for the remainder of the day following treatment.

At Healing and Psychiatry in Flagstaff, every Spravato session follows these established safety protocols. The controlled clinical setting ensures that the treatment is delivered responsibly and that patients are supported throughout each visit. Comparing FDA-approved Spravato treatment to recreational drug use is not only inaccurate – it can discourage patients who may genuinely benefit from seeking the care they need.

Myth #3: Spravato Provides Instant, Permanent Relief

On the opposite end of the spectrum from skepticism is the myth of a miracle cure. Some online sources suggest that Spravato delivers immediate and lasting results after a single session. While many patients do experience improvement more rapidly than with traditional antidepressants, setting realistic expectations is essential.

What the Evidence Actually Shows

Clinical research has demonstrated that some patients notice improvement in depressive symptoms within hours to days of their first Spravato session. However, this is not universal. Treatment response varies from person to person, and the full benefit of Spravato often becomes apparent over the course of a structured treatment plan that includes multiple sessions.

The standard Spravato protocol involves:

1. Induction phase: Typically twice-weekly sessions for the first four weeks.
2. Maintenance phase: Sessions are gradually reduced in frequency – often to once weekly and then to once every one to two weeks – based on the patient’s response.

It is also important to understand that Spravato is generally used in conjunction with an oral antidepressant, not as a standalone replacement. The combination approach is part of the FDA-approved treatment protocol. Patients at Healing and Psychiatry receive a comprehensive treatment plan that accounts for these realities, ensuring that expectations are aligned with evidence-based outcomes.

Myth #4: Spravato Is Too New or Experimental to Trust

Some patients express concern that Spravato has not been studied long enough to be considered safe or reliable. While it is reasonable to ask questions about any medication, calling Spravato “experimental” in 2026 does not accurately reflect its clinical track record.

Years of Clinical Evidence

Spravato received its initial FDA approval in March 2019, meaning it has now been in clinical use for over seven years. During that time, a growing body of real-world data has supplemented the original clinical trial findings. Long-term safety studies have continued, and post-market surveillance has provided additional insights into the medication’s profile.

Key points to consider include:

• The underlying compound, ketamine, has been used in medical settings since the 1960s, giving researchers decades of data on its pharmacology and safety.
• Spravato’s approval was based on multiple Phase III clinical trials involving hundreds of patients.
• Ongoing research in 2026 continues to refine our understanding of optimal dosing, long-term maintenance strategies, and patient selection criteria.

Patients in Flagstaff and throughout Northern Arizona who are exploring Spravato at Healing and Psychiatry can feel confident that the treatment is supported by a robust and growing evidence base – not a preliminary experiment.

Myth #5: The Side Effects Are Too Severe to Be Worth It

Concerns about side effects are valid and should always be discussed openly with a healthcare provider. However, the myth that Spravato side effects are uniformly severe or intolerable does not reflect the experience of most patients.

Common Side Effects in Context

The most frequently reported side effects of Spravato include dissociation (a temporary feeling of disconnection from surroundings), dizziness, nausea, sedation, and increased blood pressure. These effects are typically mild to moderate and tend to resolve within one to two hours after administration – which is one reason patients are monitored in the clinic after each session.

Several important considerations help put these side effects in perspective:

• Side effects often diminish with subsequent sessions as the body adjusts to the medication.
• The clinical monitoring period at the treatment facility is specifically designed to manage and observe any side effects in real time.
• Blood pressure is checked before and after each session to ensure patient safety.
• For many patients with treatment-resistant depression, the potential benefits of symptom improvement may outweigh the temporary discomfort of manageable side effects.

At Healing and Psychiatry, the clinical team discusses potential side effects thoroughly during the consultation process, ensuring that every patient can make an informed decision before beginning treatment.

Making an Informed Decision About Spravato

Misinformation can be a significant barrier to care, especially for patients already navigating the challenges of treatment-resistant depression. Whether the concern is rooted in wondering if IV ketamine is better than Spravato, worrying about side effects, or questioning whether the treatment is legitimate, the best antidote to myth is reliable, evidence-based information paired with personalized clinical guidance.

Spravato is not a perfect solution for every patient, and no responsible provider would claim otherwise. But for many individuals who have not responded adequately to traditional antidepressants, it represents a meaningful and well-studied option that may help improve quality of life.

If you are in Flagstaff, AZ, or the surrounding Northern Arizona area and have questions about whether Spravato may be appropriate for your situation, the team at Healing and Psychiatry is here to help. We encourage you to reach out and schedule a consultation to discuss your treatment history, ask questions, and explore your options in a supportive, judgment-free clinical environment. Your path toward feeling better deserves to be built on facts – not myths.